NCT06744998Not yet recruiting
Hemopatch Implication After Axillary Dissection for Breast Cancer
Hemopatch Implication After Axillary Dissection for Breast Cancer: a Randomized Clinical Study
Source: ClinicalTrials.gov · Last updated 20 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Aim of this randomized study is to assess the value of a different haemostatic sealant, the Hemopatch®, in axillary lymph node dissection (ALND) to reduce the incidence of seroma and seroma-related complications.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- Feb 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- European Institute of Oncology
- Diseases
- Childhood cancers
- NCT number
- NCT06744998
What you commit to
- Study type: Interventional
- Planned participants: 190
- From Feb 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous axillary surgery
Who the study is looking for
- Patients with primary breast cancer
- Mastectomy or breast conserving surgery
- Patients eligible for axillary dissection
- Male or female
- Any age
- Previous (or not) neoadjuvant treatments
- Any breast histotypes
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| European Institute of Oncology Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.